QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study 期刊论文 CLINICAL COLORECTAL CANCER, 2017, 卷号: 16, 期号: 2, 页码: E73-E88 作者:  Cheng, Ann-Lii;  Cornelio, Gerardo;  Shen, Lin;  Price, Timothy;  Yang, Tsai-Sheng 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/12 Depth of response  Dosing schedule  Early tumor shrinkage  Erbitux  mCRC   Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors 期刊论文 CLINICAL PHARMACOKINETICS, 2017, 卷号: 56, 期号: 1, 页码: 65-76 作者:  Yu, Mingming;  Gao, Zhiwei;  Dai, Xiaojian;  Gong, Hui;  Zhang, Lianshan 收藏  |  浏览/下载：21/0  |  提交时间：2019/01/08 The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data 期刊论文 2015, 卷号: 36, 期号: 7, 页码: 841-846 作者:  Gu, Jie-mei;  Wang, Li;  Lin, Hua;  Chen, De-cai;  Tang, Hai 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 risedronate  pyridinyl bisphosphonate  postmenopausal osteoporosis  bone density  biological markers  adverse reaction  drug administration schedule  double-blind method  female